铁羧基麦芽糖脱敏与激发的经验。

IF 3.9 2区医学 Q2 ALLERGY

World Allergy Organization Journal Pub Date : 2025-02-01 DOI:10.1016/j.waojou.2024.101025

Fatma Dindar Çelik MD , Kurtuluş Aksu MD , Özgür Akkale MD , Hatice Çelik Tuğlu MD , Melis Yağdıran MD , Onur Telli MD , Gürgün Tuğçe Vural Solak MD , Enes Çelik MD

{"title":"铁羧基麦芽糖脱敏与激发的经验。","authors":"Fatma Dindar Çelik MD , Kurtuluş Aksu MD , Özgür Akkale MD , Hatice Çelik Tuğlu MD , Melis Yağdıran MD , Onur Telli MD , Gürgün Tuğçe Vural Solak MD , Enes Çelik MD","doi":"10.1016/j.waojou.2024.101025","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>To present the characteristics of drug hypersensitivity reactions (DHR) among iron preparations and to describe the outcomes of rapid drug desensitization (RDD) and drug provocation tests (DPT) of ferric carboxymaltose (FCM).</div></div><div><h3>Methods</h3><div>The retrospective descriptive study comprised patients with hypersensitivy to iron supplements. Low-risk according to the index reaction with iron, 10 patients underwent a 4-step DPT with FCM; an 11-step RDD protocol was administered to 21 patients not classified as low-risk. RDD success was evaluated for each cycle separately, defining successful completion as the implementation of all steps in both RDD and DPT protocols without subsequent early and/or late reactions.</div></div><div><h3>Results</h3><div>Among the 21 patients (mean age: 41.73 ± 10.98 years, all female) hypersensitive to iron underwent FCM RDD, 20 patients (95.2%) successfully completed FCM treatment with RDD. RDD failed in only 1 patient (4.8%). The total number of desensitization cycles was 29, of which 28 (96.5%) were successful. Urticaria was the most common breakthrough hypersensitivity reaction and observed in 7 (33.3%) patients. Ten patients received FCM with DPT. The iron replacement therapy for these 10 patients was successfully completed. Urticaria developed in 2 patients after the completion of DPT.</div></div><div><h3>Conclusions</h3><div>RDD is a dependable procedure facilitating the efficient delivery and completion of FCM treatments in patients with iron hypersensitivity. Additionally, FCM can be applied with DPT in low-risk patients.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 2","pages":"Article 101025"},"PeriodicalIF":3.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787419/pdf/","citationCount":"0","resultStr":"{\"title\":\"The experiences of ferric carboxymaltose desensitization and provocation\",\"authors\":\"Fatma Dindar Çelik MD , Kurtuluş Aksu MD , Özgür Akkale MD , Hatice Çelik Tuğlu MD , Melis Yağdıran MD , Onur Telli MD , Gürgün Tuğçe Vural Solak MD , Enes Çelik MD\",\"doi\":\"10.1016/j.waojou.2024.101025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>To present the characteristics of drug hypersensitivity reactions (DHR) among iron preparations and to describe the outcomes of rapid drug desensitization (RDD) and drug provocation tests (DPT) of ferric carboxymaltose (FCM).</div></div><div><h3>Methods</h3><div>The retrospective descriptive study comprised patients with hypersensitivy to iron supplements. Low-risk according to the index reaction with iron, 10 patients underwent a 4-step DPT with FCM; an 11-step RDD protocol was administered to 21 patients not classified as low-risk. RDD success was evaluated for each cycle separately, defining successful completion as the implementation of all steps in both RDD and DPT protocols without subsequent early and/or late reactions.</div></div><div><h3>Results</h3><div>Among the 21 patients (mean age: 41.73 ± 10.98 years, all female) hypersensitive to iron underwent FCM RDD, 20 patients (95.2%) successfully completed FCM treatment with RDD. RDD failed in only 1 patient (4.8%). The total number of desensitization cycles was 29, of which 28 (96.5%) were successful. Urticaria was the most common breakthrough hypersensitivity reaction and observed in 7 (33.3%) patients. Ten patients received FCM with DPT. The iron replacement therapy for these 10 patients was successfully completed. Urticaria developed in 2 patients after the completion of DPT.</div></div><div><h3>Conclusions</h3><div>RDD is a dependable procedure facilitating the efficient delivery and completion of FCM treatments in patients with iron hypersensitivity. Additionally, FCM can be applied with DPT in low-risk patients.</div></div>\",\"PeriodicalId\":54295,\"journal\":{\"name\":\"World Allergy Organization Journal\",\"volume\":\"18 2\",\"pages\":\"Article 101025\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787419/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Allergy Organization Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1939455124001571\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Allergy Organization Journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1939455124001571","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：介绍铁制剂中药物超敏反应（DHR）的特点，描述三羧基麦芽糖铁（FCM）的快速药物脱敏（RDD）和药物激发试验（DPT）的结果。方法：回顾性描述性研究包括对铁补充剂过敏的患者。根据与铁的指数反应，10例患者接受了4步DPT和FCM；对21名未被归类为低风险的患者实施11步RDD方案。对每个周期分别评估RDD成功，将成功完成定义为RDD和DPT协议中所有步骤的实现，没有后续的早期和/或晚期反应。结果：21例铁过敏患者（平均年龄：41.73±10.98岁，均为女性）行FCM RDD治疗，20例（95.2%）患者成功完成FCM治疗合并RDD。只有1例（4.8%）患者RDD失败。总共29次脱敏循环，其中28次（96.5%）脱敏成功。荨麻疹是最常见的突破性超敏反应，7例（33.3%）患者出现。10例患者接受FCM合并DPT。10例患者均成功完成铁替代治疗。2例患者在DPT完成后出现荨麻疹。结论：RDD是一种可靠的方法，可促进铁过敏患者FCM治疗的有效交付和完成。此外，FCM可与DPT一起应用于低危患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The experiences of ferric carboxymaltose desensitization and provocation

Background

To present the characteristics of drug hypersensitivity reactions (DHR) among iron preparations and to describe the outcomes of rapid drug desensitization (RDD) and drug provocation tests (DPT) of ferric carboxymaltose (FCM).

Methods

The retrospective descriptive study comprised patients with hypersensitivy to iron supplements. Low-risk according to the index reaction with iron, 10 patients underwent a 4-step DPT with FCM; an 11-step RDD protocol was administered to 21 patients not classified as low-risk. RDD success was evaluated for each cycle separately, defining successful completion as the implementation of all steps in both RDD and DPT protocols without subsequent early and/or late reactions.

Results

Among the 21 patients (mean age: 41.73 ± 10.98 years, all female) hypersensitive to iron underwent FCM RDD, 20 patients (95.2%) successfully completed FCM treatment with RDD. RDD failed in only 1 patient (4.8%). The total number of desensitization cycles was 29, of which 28 (96.5%) were successful. Urticaria was the most common breakthrough hypersensitivity reaction and observed in 7 (33.3%) patients. Ten patients received FCM with DPT. The iron replacement therapy for these 10 patients was successfully completed. Urticaria developed in 2 patients after the completion of DPT.

Conclusions

RDD is a dependable procedure facilitating the efficient delivery and completion of FCM treatments in patients with iron hypersensitivity. Additionally, FCM can be applied with DPT in low-risk patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

World Allergy Organization Journal Immunology and Microbiology-Immunology

CiteScore

9.10

自引率

5.90%

发文量

审稿时长

9 weeks

期刊介绍： The official pubication of the World Allergy Organization, the World Allergy Organization Journal (WAOjournal) publishes original mechanistic, translational, and clinical research on the topics of allergy, asthma, anaphylaxis, and clincial immunology, as well as reviews, guidelines, and position papers that contribute to the improvement of patient care. WAOjournal publishes research on the growth of allergy prevalence within the scope of single countries, country comparisons, and practical global issues and regulations, or threats to the allergy specialty. The Journal invites the submissions of all authors interested in publishing on current global problems in allergy, asthma, anaphylaxis, and immunology. Of particular interest are the immunological consequences of climate change and the subsequent systematic transformations in food habits and their consequences for the allergy/immunology discipline.